Steroid sparing effects of doxofylline

Research output: Contribution to journalArticlepeer-review

18 Citations (Scopus)
445 Downloads (Pure)

Abstract

Glucocorticosteroids are widely used in the treatment of asthma and chronic obstructive pulmonary disease (COPD). However, there are growing concerns about the side effect profile of this class of drug, particularly an increased risk of pneumonia. Over the last two decades there have been many attempts to find drugs to allow a reduction of glucocorticosteroids, including xanthines such as theophylline. Use of xanthines has been shown to lead to a reduction in the requirement for glucocorticosteroids, although xanthines also have a narrow therapeutic window limiting their wider use. Doxofylline is another xanthine that has been shown to be of clinical benefit in patients with asthma or COPD, but to have a wider therapeutic window than theophylline. In the present study we have demonstrated that doxofylline produces a clear steroid sparing effect in both an allergic and a non-allergic model of lung inflammation. Thus, we have shown that concomitant treatment with a low dose of doxofylline and a low dose of the glucocorticosteroid dexamethasone (that alone had no effect) significantly reduced both allergen-induced eosinophil infiltration into the lungs of allergic mice, and lipopolysaccharide (LPS)-induced neutrophil infiltration into the lung, equivalent to a higher dose of each drug. Our results suggest that doxofylline demonstrates significant anti-inflammatory activity in the lung which can result in significant steroid sparing activity.

Original languageEnglish
JournalPulmonary pharmacology & therapeutics
Early online date16 Oct 2017
DOIs
Publication statusPublished - Feb 2018

Keywords

  • Doxofylline
  • Steroid sparing
  • Lung
  • Inflammation

Fingerprint

Dive into the research topics of 'Steroid sparing effects of doxofylline'. Together they form a unique fingerprint.

Cite this